Cargando…

A Markov Model Approach Assessing the Cost of Illness of Generalized Anxiety Disorder in Canada

INTRODUCTION: Generalized anxiety disorder (GAD) is a chronic disease with waxing and waning of symptoms. This is the first comprehensive economic model developed to reflect the nature and course of GAD. METHODS: An incidence-based probabilistic Markov model was developed reflecting nine GAD health...

Descripción completa

Detalles Bibliográficos
Autores principales: Bereza, Basil G., Machado, Márcio, Papadimitropoulos, Manny, Sproule, Beth, Ravindran, Arun V., Einarson, Thomas R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare Communications 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4389036/
https://www.ncbi.nlm.nih.gov/pubmed/26000207
http://dx.doi.org/10.1007/s40120-012-0001-y
_version_ 1782365473607778304
author Bereza, Basil G.
Machado, Márcio
Papadimitropoulos, Manny
Sproule, Beth
Ravindran, Arun V.
Einarson, Thomas R.
author_facet Bereza, Basil G.
Machado, Márcio
Papadimitropoulos, Manny
Sproule, Beth
Ravindran, Arun V.
Einarson, Thomas R.
author_sort Bereza, Basil G.
collection PubMed
description INTRODUCTION: Generalized anxiety disorder (GAD) is a chronic disease with waxing and waning of symptoms. This is the first comprehensive economic model developed to reflect the nature and course of GAD. METHODS: An incidence-based probabilistic Markov model was developed reflecting nine GAD health states (HS): clinical assessments (three HS), maintenance therapies (four HS), discontinuation (one HS), and death (one HS). A probability curve of the GAD onset (ages 18–80) determined entry into the model and assumed patients retained the diagnoses until death. Canadian Psychiatric Association (CPA) guidelines determined pharmacotherapy, with revisions/validation by an expert panel. Direct costs (clinician, pharmacotherapy, hospitalization) were retrieved from government publications. Remission was based on pooled-analysis of CPA-cited evidence. Remaining clinical rates, absenteeism, and hospitalization were retrieved from the literature. Direct costs were attributed throughout the model except for the discontinuation and death HS. Indirect costs (wage rate) were retrieved from government publications and the literature (absenteeism), and were attributed to patients with GAD ≤65 years of age. Results were discounted at 5% and results expressed in 2008 Canadian dollars. RESULTS: The mean lifetime cost of illness (COI) was estimated to be $31,213 (SD $9,100) per patient. The cost of absenteeism accounted for 96% of the mean COI. The mean age of onset was 31 years and approximately 19% did not respond to pharmacotherapy. Over 85% of patients discontinued treatment by the fourth cycle (2nd year of therapy). Over the course of the model, a mean of 53% of patients relapsed, with an average rate of 0.79 relapses per patient. On average and over a lifetime, the disorder went unmanaged over a period of 14 (SD 9) years. The model was most sensitive to absenteeism. CONCLUSION: GAD is a costly disease with a lifetime COI <$32k/patient, with absenteeism exerting a significant impact.
format Online
Article
Text
id pubmed-4389036
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Springer Healthcare Communications
record_format MEDLINE/PubMed
spelling pubmed-43890362015-05-21 A Markov Model Approach Assessing the Cost of Illness of Generalized Anxiety Disorder in Canada Bereza, Basil G. Machado, Márcio Papadimitropoulos, Manny Sproule, Beth Ravindran, Arun V. Einarson, Thomas R. Neurol Ther Original Research INTRODUCTION: Generalized anxiety disorder (GAD) is a chronic disease with waxing and waning of symptoms. This is the first comprehensive economic model developed to reflect the nature and course of GAD. METHODS: An incidence-based probabilistic Markov model was developed reflecting nine GAD health states (HS): clinical assessments (three HS), maintenance therapies (four HS), discontinuation (one HS), and death (one HS). A probability curve of the GAD onset (ages 18–80) determined entry into the model and assumed patients retained the diagnoses until death. Canadian Psychiatric Association (CPA) guidelines determined pharmacotherapy, with revisions/validation by an expert panel. Direct costs (clinician, pharmacotherapy, hospitalization) were retrieved from government publications. Remission was based on pooled-analysis of CPA-cited evidence. Remaining clinical rates, absenteeism, and hospitalization were retrieved from the literature. Direct costs were attributed throughout the model except for the discontinuation and death HS. Indirect costs (wage rate) were retrieved from government publications and the literature (absenteeism), and were attributed to patients with GAD ≤65 years of age. Results were discounted at 5% and results expressed in 2008 Canadian dollars. RESULTS: The mean lifetime cost of illness (COI) was estimated to be $31,213 (SD $9,100) per patient. The cost of absenteeism accounted for 96% of the mean COI. The mean age of onset was 31 years and approximately 19% did not respond to pharmacotherapy. Over 85% of patients discontinued treatment by the fourth cycle (2nd year of therapy). Over the course of the model, a mean of 53% of patients relapsed, with an average rate of 0.79 relapses per patient. On average and over a lifetime, the disorder went unmanaged over a period of 14 (SD 9) years. The model was most sensitive to absenteeism. CONCLUSION: GAD is a costly disease with a lifetime COI <$32k/patient, with absenteeism exerting a significant impact. Springer Healthcare Communications 2012-06-07 /pmc/articles/PMC4389036/ /pubmed/26000207 http://dx.doi.org/10.1007/s40120-012-0001-y Text en © The Author(s) 2012 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
spellingShingle Original Research
Bereza, Basil G.
Machado, Márcio
Papadimitropoulos, Manny
Sproule, Beth
Ravindran, Arun V.
Einarson, Thomas R.
A Markov Model Approach Assessing the Cost of Illness of Generalized Anxiety Disorder in Canada
title A Markov Model Approach Assessing the Cost of Illness of Generalized Anxiety Disorder in Canada
title_full A Markov Model Approach Assessing the Cost of Illness of Generalized Anxiety Disorder in Canada
title_fullStr A Markov Model Approach Assessing the Cost of Illness of Generalized Anxiety Disorder in Canada
title_full_unstemmed A Markov Model Approach Assessing the Cost of Illness of Generalized Anxiety Disorder in Canada
title_short A Markov Model Approach Assessing the Cost of Illness of Generalized Anxiety Disorder in Canada
title_sort markov model approach assessing the cost of illness of generalized anxiety disorder in canada
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4389036/
https://www.ncbi.nlm.nih.gov/pubmed/26000207
http://dx.doi.org/10.1007/s40120-012-0001-y
work_keys_str_mv AT berezabasilg amarkovmodelapproachassessingthecostofillnessofgeneralizedanxietydisorderincanada
AT machadomarcio amarkovmodelapproachassessingthecostofillnessofgeneralizedanxietydisorderincanada
AT papadimitropoulosmanny amarkovmodelapproachassessingthecostofillnessofgeneralizedanxietydisorderincanada
AT sproulebeth amarkovmodelapproachassessingthecostofillnessofgeneralizedanxietydisorderincanada
AT ravindranarunv amarkovmodelapproachassessingthecostofillnessofgeneralizedanxietydisorderincanada
AT einarsonthomasr amarkovmodelapproachassessingthecostofillnessofgeneralizedanxietydisorderincanada
AT berezabasilg markovmodelapproachassessingthecostofillnessofgeneralizedanxietydisorderincanada
AT machadomarcio markovmodelapproachassessingthecostofillnessofgeneralizedanxietydisorderincanada
AT papadimitropoulosmanny markovmodelapproachassessingthecostofillnessofgeneralizedanxietydisorderincanada
AT sproulebeth markovmodelapproachassessingthecostofillnessofgeneralizedanxietydisorderincanada
AT ravindranarunv markovmodelapproachassessingthecostofillnessofgeneralizedanxietydisorderincanada
AT einarsonthomasr markovmodelapproachassessingthecostofillnessofgeneralizedanxietydisorderincanada